Cases & Investigations

Neurontin Antitrust Litigation

PRACTICE AREAS: Antitrust
PRODUCT: Neurontin
CASE STATUS: Settled
SETTLEMENT AMOUNT: $190 million
COURT: United States District Court for the District of New Jersey

Berger & Montague helped obtain a $190 million settlement on behalf of a class of direct purchasers of the brand-name prescription drug Neurontin.

The Neurontin class alleged that Pfizer, Inc., one of the nation’s largest pharmaceutical manufacturers, and its subsidiary Warner-Lambert Co., illegally maintained a monopoly in the market for Neurontin, a popular anti-epilepsy drug, by filing sham patent litigation against generic competitors in order to delay the marketing of less expensive generic substitutes for Neurontin. The lawsuit alleged that, as a result, all purchasers paid artificially inflated prices for the Neurontin drug entity, in violation of the federal antitrust laws.

Lead Attorneys

David Sorensen Headshot

David F. Sorensen

Managing Shareholder

Request A Free Consultation

  • This field is for validation purposes and should be left unchanged.